Clinical course of 161 untreated and tenofovir-treated chronic hepatitis B pregnant patients in a low hepatitis B virus endemic region

Journal of Viral Hepatitis

Volumn 23, Issue 1, 2016, Pages 15-22

  Samadi Kochaksaraei, G ^a   Castillo, E ^a   Osman, M ^b   Simmonds, K ^b   Scott, A N ^b   Oshiomogho, J I ^a   Lee, S S ^a   Myers, R P ^a   Martin, S R ^c   Coffin, C S ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b ALBERTA ENVIRONMENT AND PARKS   (Canada)

^c ALBERTA CHILDREN'S HOSPITAL   (Canada)

Author keywords

chronic hepatitis B; perinatal transmission; pregnancy; tenofovir disoproxil fumarate

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS B ANTIBODY; HEPATITIS B(E) ANTIGEN; TENOFOVIR; VIRUS DNA; ANTIVIRUS AGENT; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE;

ADULT; ARTICLE; CANADIAN; CESAREAN SECTION; CHILDBIRTH; CHRONIC HEPATITIS B; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; DISEASE EXACERBATION; DRUG TOLERABILITY; ENDEMIC DISEASE; FEMALE; FOLLOW UP; HEPATITIS B VIRUS; HUMAN; IMMUNOPROPHYLAXIS; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; PATIENT COMPLIANCE; PATIENT SELECTION; PREGNANCY; PREGNANT WOMAN; PRIORITY JOURNAL; PUERPERIUM; THIRD TRIMESTER PREGNANCY; TREATMENT REFUSAL; VERTICAL TRANSMISSION; VIREMIA; VIRUS CARRIER; VIRUS LOAD; BLOOD; CANADA; DRUG EFFECTS; HEPATITIS B, CHRONIC; IMMUNOLOGY; INFANT; ISOLATION AND PURIFICATION; NEWBORN; PREGNANCY COMPLICATIONS, INFECTIOUS; PREVENTION AND CONTROL; PROSPECTIVE STUDY; TRANSMISSION; TREATMENT OUTCOME; VIROLOGY;

ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; CANADA; COHORT STUDIES; FEMALE; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INFANT; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PROSPECTIVE STUDIES; TENOFOVIR; TREATMENT OUTCOME; VIRAL LOAD; VIREMIA;

EID: 84954075918     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12436     Document Type: Article

References (37)

1. WHO. Hepatitis B: World Health Organization fact sheet 204 (revised July 2014). Available at http://www.who.int/mediacentre/factsheets/fs204/en. (accessed 15 November 2014)
2. Lok AS, McMahon BJ,. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-662
3. McMahon BJ, Alward WL, Hall DB, et al,. Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. J Infect Dis 1985; 151: 599-603
4. Zanetti AR, Van Damme P, Shouval D,. The global impact of vaccination against hepatitis B: a historical overview. Vaccine 2008; 26: 6266-6273
5. Shepard CW, Simard EP, Finelli L, Fiore AE, Bell BP,. Hepatitis B virus infection: epidemiology and vaccination. Epidemiol Rev 2006; 28: 112-125
6. Song YM, Sung J, Yang S, Choe YH, Chang YS, Park WS,. Factors associated with immunoprophylaxis failure against vertical transmission of hepatitis B virus. Eur J Pediatr 2007; 166: 813-818
7. Chen HL, Lin LH, Hu FC, et al,. Effects of maternal screening and universal immunization to prevent mother-to-infant transmission of HBV. Gastroenterology 2012; 142: 773-781
8. Wiseman E, Fraser MA, Holden S, et al,. Perinatal transmission of hepatitis B virus: an Australian experience. Med J Aust 2009; 190: 489-492
9. Zou H, Chen Y, Duan Z, Zhang H, Pan C,. Virologic factors associated with failure to passive-active immunoprophylaxis in infants born to HBsAg-positive mothers. J Viral Hepat 2012; 19: e18-e25
10. Yi W, Pan CQ, Hao J, et al,. Risk of vertical transmission of hepatitis B after amniocentesis in HBs antigen-positive mothers. J Hepatol 2014; 60: 523-529
11. Tharmaphornpilas P, Rasdjarmrearnsook AO, Plianpanich S, Sa-nguanmoo P, Poovorawan Y,. Increased risk of developing chronic HBV infection in infants born to chronically HBV infected mothers as a result of delayed second dose of hepatitis B vaccination. Vaccine 2009; 27: 6110-6115
12. EASL clinical practice guidelines. Management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-185
13. Coffin CS, Fung SK, Ma MM,. Management of chronic hepatitis B: consensus guidelines. Can J Gastroenterol 2012; 26: 917-938
14. Pan CQ, Duan ZP, Bhamidimarri KR, et al,. An algorithm for risk assessment and intervention of mother to child transmission of hepatitis B virus. Clin Gastroenterol Hepatol 2012; 10: 452-459
15. Xu WM, Cui YT, Wang L, et al,. Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study. J Viral Hepat 2009; 16: 94-103
16. van Zonneveld M, van Nunen AB, Niesters HG, de Man RA, Schalm SW, Janssen HL,. Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection. J Viral Hepat 2003; 10: 294-297
17. Chayama K, Suzuki Y, Kobayashi M, et al,. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology 1998; 27: 1711-1716
18. Han GR, Cao MK, Zhao W, et al,. A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection. J Hepatol 2011; 55: 1215-1221
19. Pan CQ, Han GR, Jiang HX, et al,. Telbivudine prevents vertical transmission from HBeAg-positive women with chronic hepatitis B. Clin Gastroenterol Hepatol 2012; 10: 520-526
20. Buti M, Tsai N, Petersen J, et al,. Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B Virus infection. Dig Dis Sci 2015; 60: 1457-1464
21. Baroncelli S, Tamburrini E, Ravizza M, et al,. Antiretroviral treatment in pregnancy: a six-year perspective on recent trends in prescription patterns, viral load suppression, and pregnancy outcomes. AIDS Patient Care STDS 2009; 23: 513-520
22. Ransom CE, Huo Y, Patel K, et al,. Infant growth outcomes after maternal tenofovir disoproxil fumarate use during pregnancy. J Acquir Immune Defic Syndr 2013; 64: 374-381
23. Brown RS Jr, Verna EC, Pereira MR, et al,. Hepatitis B virus and human immunodeficiency virus drugs in pregnancy: findings from the Antiretroviral Pregnancy Registry. J Hepatol 2012; 57: 953-959
24. Pan CQ, Mi LJ, Bunchorntavakul C, et al,. Tenofovir disoproxil fumarate for prevention of vertical transmission of hepatitis B virus infection by highly viremic pregnant women: a case series. Dig Dis Sci 2012; 57: 2423-2429
25. Greenup AJ, Tan PK, Nguyen V, et al,. Efficacy and safety of tenofovir disoproxil fumarate in pregnancy to prevent perinatal transmission of hepatitis B virus. J Hepatol 2014; 61: 502-507
26. Celen MK, Mert D, Ay M, et al,. Efficacy and safety of tenofovir disoproxil fumarate in pregnancy for the prevention of vertical transmission of HBV infection. World J Gastroenterol 2013; 19: 9377-9382
27. Nguyen V, Tan PK, Greenup AJ, et al,. Anti-viral therapy for prevention of perinatal HBV transmission: extending therapy beyond birth does not protect against post-partum flare. Aliment Pharmacol Ther 2014; 39: 1225-1234
28. Coffin CS, Lee SS,. Editorial: Anti-viral therapy for prevention of perinatal HBV transmission-extending therapy beyond birth and the risk of post-partum flare. Aliment Pharmacol Ther 2014; 40: 115-116
29. Plitt SS, Somily AM, Singh AE,. Outcomes from a Canadian public health prenatal screening program for hepatitis B: 1997-2004. Can J Public Health 2007; 98: 194-197
30. Olsen IE, Groveman SA, Lawson ML, Clark RH, Zemel BS,. New intrauterine growth curves based on United States data. Pediatrics 2010; 125: e214-e224
31. Ayres A, Yuen L, Jackson KM, et al,. Short duration of lamivudine for the prevention of hepatitis B virus transmission in pregnancy: lack of potency and selection of resistance mutations. J Viral Hepat 2014; 21: 809-817
32. Liu M, Cai H, Yi W,. Safety of telbivudine treatment for chronic hepatitis B for the entire pregnancy. J Viral Hepat 2013; 20 (Suppl 1): 65-70
33. Gaunt G, Ramin K,. Immunological tolerance of the human fetus. Am J Perinatol 2001; 18: 299-312
34. ter Borg MJ, Leemans WF, de Man RA, Janssen HL,. Exacerbation of chronic hepatitis B infection after delivery. J Viral Hepat 2008; 15: 37-41
35. Giles M, Visvanathan K, Lewin S, et al,. Clinical and virological predictors of hepatic flares in pregnant women with chronic hepatitis B. Gut 2014; doi: 10.1136/gutjnl-2014-308211. [Epub ahead of print]
36. Raimondo G, Pollicino T, Romano L, Zanetti AR,. A 2010 update on occult hepatitis B infection. Pathol Biol (Paris) 2010; 58: 254-257
37. Pande C, Sarin SK, Patra S, et al,. Hepatitis B vaccination with or without hepatitis B immunoglobulin at birth to babies born of HBsAg-positive mothers prevents overt HBV transmission but may not prevent occult HBV infection in babies: a randomized controlled trial. J Viral Hepat 2013; 20: 801-810